LY305

LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.
Wikipedia contributors, "LY305", Wikipedia, revision 1361910489, retrieved 20 November 2026, source, CC BY-SA 4.0.